跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 大樑
主治醫師
,
臺北市立萬芳醫院
https://orcid.org/0000-0002-1156-2389
電子郵件
tlc
tmu.edu
tw
h-index
5551
引文
43
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1986 …
2025
每年研究成果
概覽
指紋
網路
專案
(18)
研究成果
(249)
資料集
(2)
類似的個人檔案
(12)
指紋
查看啟用 Ta-Liang Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Acupuncture Treatment
17%
Acute Kidney Injury
9%
Adverse Event
25%
Adverse Outcome
75%
Anesthesiologist
16%
Anesthesiology
8%
Apoplexy
100%
Auriculotherapy
11%
Cardiopulmonary Bypass
9%
Cholestin
9%
Chronic Kidney Disease
9%
Cohort Analysis
63%
Diabetes
30%
Disease
9%
Emergency Care
7%
Gastrointestinal Bleeding
8%
Gene Expression
11%
General Anesthesia
15%
Geriatrics
15%
Hazard Ratio
24%
Hemodynamic
13%
Hospital Mortality
18%
Immunoglobulin Enhancer Binding Protein
7%
Influenza Vaccination
16%
Intensive Care Unit
11%
Intracellular Calcium
9%
Ketamine
11%
Lipopolysaccharide
13%
Liver Cirrhosis
18%
Logistic Regression Analysis
10%
Major Surgery
33%
Mental Disorder
8%
Neuraxial Anesthesia
8%
Nitric Oxide
14%
Noncardiac Surgery
16%
Odds Ratio
95%
Parkinson's Disease
9%
Patient with Diabetes
12%
Patient with Epilepsy
10%
Postoperative Complication
25%
Prevalence
7%
Propensity Score Matching
10%
Propofol
23%
Prostaglandin E1
7%
Retrospective Cohort Study
69%
Septicemia
18%
Surgical Mortality
18%
Traditional Chinese Medicine
14%
Traumatic Brain Injury
19%
Urinary Tract Infection
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
8%
Adenosine Triphosphate
9%
Adverse Event
19%
Adverse Outcome
13%
Alternative Complement Pathway C3 C5 Convertase
8%
Anti-Inflammatory Drug
10%
Antiplatelet
6%
Benzo(a)pyrene
7%
Cell Viability
9%
Chronic Kidney Failure
9%
Cohort Study
74%
Cyclooxygenase 2
7%
CYP1B1
7%
Cytochrome P450
41%
Cytochrome P450 1A1
9%
Cytokine
13%
Diabetes Mellitus
11%
End Stage Renal Disease
9%
Enflurane
8%
Ethoxyresorufin
8%
Gastrointestinal Hemorrhage
7%
Hospital Mortality
9%
Immunoglobulin Enhancer Binding Protein
7%
Interleukin 1
14%
Ketamine
29%
Lipopolysaccharide
39%
Liver Cell Carcinoma
7%
Lung Adenocarcinoma
9%
Mitogen Activated Protein Kinase
7%
Mitogen Activated Protein Kinase 3
8%
Mouse
25%
Nitric Oxide
21%
Nitroprusside Sodium
14%
Nuclear Factor
11%
Osteoarthritis
7%
Oxidized Low Density Lipoprotein
11%
Parkinson's Disease
9%
Pharmacokinetics
7%
Propofol
39%
Randomized Controlled Trial
7%
Reactive Oxygen Metabolite
12%
Surfactant Protein A
10%
Toll Like Receptor 2
7%
Toll Like Receptor 4
19%
Traditional Chinese Medicine
17%
Transcription Factor AP 1
7%
Tumor Necrosis Factor
14%
Unspecific Monooxygenase
34%
Urinary Tract Infection
11%
Western Blot
8%
Nursing and Health Professions
Adverse Event
16%
Adverse Outcome
39%
Anesthesiologist
7%
Auriculotherapy
17%
Blood Pressure
7%
Cholestin
6%
Cohort Analysis
68%
Comorbidity
7%
Confidence Interval
79%
Disease
12%
Elevated Blood Pressure
6%
Emergency Care
6%
Hazard Ratio
17%
Hospital Mortality
8%
Influenza Vaccination
9%
Intensive Care Unit
5%
Intubation
5%
Lidocaine
6%
Liver Cirrhosis
14%
Liver Surgery
6%
Logistic Regression Analysis
5%
Major Surgery
9%
Meta Analysis
14%
National Health Insurance
25%
Odds Ratio
73%
Parkinson's Disease
9%
Patient with Diabetes
5%
Perioperative
6%
Postoperative Complication
12%
Pressure Ulcer
6%
Prevalence
13%
Propensity Score
17%
Septicemia
9%
Sore Throat
6%
Surgical Mortality
7%
Systematic Review
7%
Total Knee Arthroplasty
6%
Tourniquet
5%
Traumatic Brain Injury
13%
Urinary Tract Infection
10%
